Savara Pharmaceuticals (stock symbol: SVRA) Logo in transparent PNG format

About Savara Pharmaceuticals

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

• Website domain: savarapharma.com
• Employees: 22
• Marketcap: $0.27 Billion USD